Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection

Journal of the National Cancer Institute

Volumn 105, Issue 20, 2013, Pages 1534-1539

  Haines, Ian E ^a   Gabor Miklos, George L ^b  

^a MONASH UNIVERSITY   (Australia)

^b Newport Beach   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; HUMAN; LONG TERM CARE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RADIOTHERAPY; REVIEW; UNITED STATES;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SELECTION BIAS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WATCHFUL WAITING;

EID: 84886014831     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt248     Document Type: Review

References (32)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
3. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
4. Schroder FH, Roobol MJ, ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46-52.
5. Moyer VA, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
6. Lacy SS. Press release of the president of the AUA, May 21, 2012. http://www.prnewswire.com/news-releases/aua-disputes-panels-recommendations-on- prostate-cancer-screening-152349275.html. Accessed August 13, 2013.
7. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol. 2012;30(24):3020-3025.
8. Ganz PA, Barry JM, Burke W, et al. Role of active surveillance in the management of men with localized prostate cancer. In: National Institutes of Health State-of-the-Art-Science Conference. National Institutes of Health, Bethesda, MD. 2011.
9. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
10. Attems J, Arbes S, Bohm G, et al. The clinical diagnostic accuracy rate regarding the immediate cause of death in a hospitalized geriatric population; an autopsy study of 1594 patients. Wien Med Wochenschr. 2004;154(7-8):159-162.
11. Das C. Death certificates in Germany, England, The Netherlands, Belgium and the USA. Eur J Health Law. 2005;12(3):193-211.
12. Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000:92(8):613-621.
13. Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Clin Trials. 2000;7(4):303-311.
14. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Can. 2009;126(10):2387-2393.
15. Dubben H-H. Prostate-Cancer screening. N Engl J Med. 2009;361(2):204.
16. Popiolek M, Rider JR, Andren O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63(3):428-435.
17. Wong Y-N, Freedland SJ, Egleston B, et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009;56(4):609-616.
18. Janoff DM, Peterson C, Mongoue-Tchokote S, et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int. 2005;96(4):503-507.
19. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two step process. Cancer Res. 1999;59(19):5030-5036.
20. Banach-Petrosky W, Jessen WJ, Ouyang X, et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 2007;67(19):9089-9096.
21. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
22. Theoret MR, Ning Y-M, Zhang JJ, et al. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97-99.
23. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451-459.
24. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2005;26(15):2497-2504.
25. Vasudeva P, Goel A, Dalela D. Survival following primary androgen deprivation therapy among men with localized prostate cancer. Indian J Urol. 2008;24(4):590-591.
26. Shahinian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
27. Nanda A, Chen M-H, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866-873.
28. Keating NL, O'Malley J, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39-46.
29. Van Hemelrjick M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-3456.
30. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survivalfollowing primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-181.
31. Levine GN, D'Amico AV, Berger P, et al. Androgen deprivation therapy in prostate cancer and cardiovascular risk. Circulation. 2010;121(6):833-840.
32. Brawley OW, Goldberg P. How We Do Harm. New York: St Martin's Press; 2012.